STAT+: Lilly bypasses Australian pharmacies with DTC model
Eli Lilly is launching LillyDirect to deliver Mounjaro straight to Australian patients’ doors — and local doctors and pharmacists aren’t thrilled.
Novartis has agreed to invest $575 million upfront to license an experimental mRNA-based autoimmune therapy from Chinese biotech Abogen Biosciences, marking the latest instance of a major pharmaceutical corporation turning to China to bolster its research portfolio. The deal, announced in a STAT+ report, illustrates a growing trend of international collaboration in the biotechnology sector.
Meanwhile, the National Institutes of Health has disbursed the full $34 billion allocation Congress provided in the fiscal year 2026, yet the complex and evolving funding landscape is posing challenges for researchers on the ground. The opaque nature of the funding process is hindering the ability of scientists to effectively carry out their work, highlighting the need for more straightforward and transparent financial mechanisms in the U.S. research funding system.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
